Intelligence · Clinical Pipeline
Century Therapeutics Pipeline
All ClinicalTrials.gov programs at Century Therapeutics — phase, modality, and trial IDs.
- Programs
- 5
Quick answer
Century Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product
Century Therapeutics
Hematological or solid tumor malignancies or autoimmune diseases
1 trial -
CNTY-101
Century Therapeutics
R/R CD19-Positive B-Cell Malignancies
1 trial -
CNTY-101
Century Therapeutics
Systemic Lupus Erythematosus
1 trial -
Nicotine gum (C)
Century Therapeutics
Tobacco Use
2 trials -
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune Diseases
Century Therapeutics
systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]
1 trial
Frequently asked questions
How many pipeline programs does Century Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs